Stock 300006 CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chongqing Lummy Pharmaceutical Co., Ltd.

Equities

300006

CNE100000H10

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-26 pm EDT 		5-day change 1st Jan Change
2.35 CNY -2.89% Intraday chart for Chongqing Lummy Pharmaceutical Co., Ltd. -1.26% -36.83%
Jun. 05 Lummy Pharmaceutical Gets Nod to Market Naloxone Hydrochloride Injection MT
Apr. 23 Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,924 4,589 6,035 7,201 4,023 3,928
Enterprise Value (EV) 1 3,620 5,413 6,917 6,861 3,542 3,362
P/E ratio 29.8 x -29.6 x -18.5 x -67.5 x -58.5 x -438 x
Yield 1.39% 0.88% - - - -
Capitalization / Revenue 1.87 x 2.47 x 3.81 x 5.88 x 4.55 x 4.39 x
EV / Revenue 2.32 x 2.91 x 4.37 x 5.6 x 4 x 3.75 x
EV / EBITDA 16.1 x 46.1 x -1,012 x -107 x -98 x 453 x
EV / FCF 149 x -30 x 131 x -87.3 x 16.7 x 190 x
FCF Yield 0.67% -3.33% 0.76% -1.14% 5.99% 0.53%
Price to Book 1.72 x 2.95 x 5.15 x 3.34 x 1.89 x 1.89 x
Nbr of stocks (in thousands) 812,241 812,241 812,241 1,055,911 1,055,911 1,055,911
Reference price 2 3.600 5.650 7.430 6.820 3.810 3.720
Announcement Date 4/24/19 4/24/20 3/30/21 3/25/22 3/17/23 3/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,562 1,859 1,584 1,225 884.6 895.6
EBITDA 1 224.3 117.5 -6.838 -63.86 -36.13 7.428
EBIT 1 117 9.298 -115.2 -133.4 -105.9 -56.71
Operating Margin 7.49% 0.5% -7.27% -10.89% -11.97% -6.33%
Earnings before Tax (EBT) 1 109.3 -169.7 -343.6 -106 -75.25 3.594
Net income 1 98 -155.2 -326.8 -100.5 -68.71 -8.927
Net margin 6.27% -8.35% -20.64% -8.2% -7.77% -1%
EPS 2 0.1210 -0.1911 -0.4023 -0.1010 -0.0651 -0.008500
Free Cash Flow 1 24.33 -180.2 52.62 -78.55 212.1 17.68
FCF margin 1.56% -9.69% 3.32% -6.41% 23.98% 1.97%
FCF Conversion (EBITDA) 10.85% - - - - 238.05%
FCF Conversion (Net income) 24.82% - - - - -
Dividend per Share 2 0.0500 0.0500 - - - -
Announcement Date 4/24/19 4/24/20 3/30/21 3/25/22 3/17/23 3/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1
Net sales -
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 -26.4
Net margin -
EPS 2 -0.0250
Dividend per Share -
Announcement Date 4/26/22
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 696 824 882 - - -
Net Cash position 1 - - - 340 481 566
Leverage (Debt/EBITDA) 3.105 x 7.013 x -129 x - - -
Free Cash Flow 1 24.3 -180 52.6 -78.6 212 17.7
ROE (net income / shareholders' equity) 5.29% -9.56% -23.9% -6.15% -3.47% -0.47%
ROA (Net income/ Total Assets) 2.49% 0.17% -2.17% -2.75% -2.21% -1.19%
Assets 1 3,940 -88,735 15,091 3,661 3,105 748.9
Book Value Per Share 2 2.090 1.920 1.440 2.040 2.010 1.970
Cash Flow per Share 2 0.3900 0.5400 0.6700 0.5300 0.8000 0.7900
Capex 1 126 63.1 44.5 50.3 68.2 59.3
Capex / Sales 8.06% 3.39% 2.81% 4.1% 7.71% 6.62%
Announcement Date 4/24/19 4/24/20 3/30/21 3/25/22 3/17/23 3/22/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CHONGQING LUMMY PHARMACEUTICAL CO., LTD. Stock Chongqing Lummy Pharmaceutical Co., Ltd.
-36.83% 341M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.95% 819B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.93% 638B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.98% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.08% 329B
ABBVIE INC. Stock AbbVie Inc.
+9.05% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.79% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.25% 225B
NOVARTIS AG Stock Novartis AG
+13.01% 217B
AMGEN INC. Stock Amgen Inc.
+8.91% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300006 Stock
  4. Financials Chongqing Lummy Pharmaceutical Co., Ltd.